Research on new class of treatments for ovarian cancer receives $725,000 in funding from Ovarian Cancer Canada to become “clinical trial-ready”

Research on new class of treatments for ovarian cancer receives $725,000 in funding from Ovarian Cancer Canada to become “clinical trial-ready”

HALIFAX, Nova Scotia, May 04, 2026 (GLOBE NEWSWIRE) -- To mark World Ovarian Cancer Day, Ovarian Cancer Canada is announcing a $725,000 investment to fuel critical ovarian cancer research. Led by globally respected Canadian immunologist, Dr. Jeanette Boudreau, investment in…

Ovarian Cancer Canada Invests $725k to Make New Class of Treatments “Clinical Trial-Ready”

Ovarian Cancer Canada is investing $725,000 to enable powerful natural killer cell immunotherapy that Dr. Jeanette Boudreau has been developing for many years to become “clinical trial-ready”. [Ovarian Cancer Canada] Press Release